KOL · Clinical Advisory · Investment Diligence

Medical Device, Pharma & Investment Advisory Services

An active clinical trialist, KOL, and published investigator — available for product development, scientific advisory boards, clinical trial leadership, and investment diligence in urologic oncology.

33Active IRB Studies
9As Principal Investigator
80+Publications
120+Talks & Presentations
Advisory Areas

How Dr. Tan Partners with Industry

Medical Device Companies

Focal ablation devices, biopsy platforms, robotic surgery, imaging, and hydrogel spacers. Engagements include product development input, KOL advisory boards, regulatory strategy, and clinical trial principal investigator roles.

Pharmaceutical Companies

Bladder cancer (intravesical therapies, immunotherapy) and prostate cancer (ADT, genomics, PET agents). Trial design, investigator-initiated studies, market access insight, and scientific advisory boards.

Venture Capital & Private Equity

Clinical diligence, market sizing, KOL network analysis, technology differentiation, and post-investment strategy across urologic oncology device, diagnostic, and therapeutic assets.

Therapeutic Focus

Areas of Deep Expertise

HIFU / Focal One Cryoablation PEF / IRE / NanoKnife Histotripsy Robotic Surgery PSMA PET Imaging MRI Fusion Biopsy AI / Genomics (ARTERA) Intravesical Therapy Immuno-Oncology Hydrogel Spacers Bladder Cancer
Industry Collaborations

Selected Clinical Trial Sponsors

Dr. Tan has served as investigator or principal investigator on studies sponsored by:

Bayer Merck / MSD Pfizer Astellas / Seagen Moderna Teleflex BlueEarth Diagnostics HistoSonics UroGen Pharma CG Oncology ImmunityBio Tyra Biosciences Syncromune Tarus Therapeutics BioProtect Photocure ECOG-ACRIN

Start an Engagement

Reach out for KOL work, advisory boards, clinical trial leadership, or investment diligence.

📞 CallBook Online